Cite
MLA Citation
M. Jebali et al.. “Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma.” BMC cancer, vol. 17, no. 1, 2017, pp. 1–7. http://access.bl.uk/ark:/81055/vdc_100080988769.0x000150